非类氨酸-血管压素对手:瓦帕坦斯
Guy Decaux1, Alain Soupart, Gilbert Vassart
1Department of Internal Medicine, Erasmus University Hospital, Brussels, Belgium. guy.decaux@skynet.be
Lancet (London, England)
|May 13, 2008
概括
瓦帕坦是针对V1a,V1b和V2受体的新型血管压素受体对抗剂. 这些药物对治疗诸如低血压,精神疾病和血管问题等疾病有前途.
科学领域:
- 内分泌学和药理学 在内分泌学和药理学
- G蛋白结合受体研究研究
背景情况:
- 氨酸-血管压素对于循环和水的平衡至关重要.
- 血管压素受体 (V1a,V1b,V2) 是G蛋白结合受体家族的一部分.
研究的目的:
- 审查血管压素受体对抗剂 (vaptans) 的开发和治疗潜力.
- 突出不同器官的选择性和非选择性行为.
主要方法:
- 对vaptans的药理学数据的审查.
- 对选择性和非选择性血管压素受体抗剂的临床应用的分析.
主要成果:
- 选择性V1a抗剂 (例如,relcovaptan) 在治疗雷诺氏病,经期障碍和毒素溶解方面显示出潜在的潜力.
- 选择性V1b抗剂 (例如,SSR-149415) 可能有利于精神疾病.
- 维2抗剂 (例如,托尔瓦普坦) 通过诱导低性尿路症来有效治疗低血症.
- 非选择性V1a/V2抗剂 (例如,康尼瓦普坦) 已被批准用于治疗低血症.
结论:
- 瓦帕坦在向血管压素受体亚型方面取得了重大进展.
- 不同的vaptans为各种疾病提供有针对性的治疗策略.
相关概念视频
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...


